Abstracts tagged "polymyalgia rheumatica and methotrexate (MTX)"

Abstract Number: 742 • 2019 ACR/ARP Annual Meeting
Polymyalgia Rheumatica: New Therapeutic Strategy Based on Low Dose Metrotexate Plus Local Infiltration with Corticosteroids
Miriam Retuerto¹, Pilar Fernández-Dapica ², Patricia Lavilla ³, Fernando Lozano ³, M. Eva Vallejo ⁴ and José Luis Pablos ⁵, ¹Rheumatology Department. Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ²Hospital universitario 12 de octubre, Instituto de investigacion hospital 12 de octubre (i+12), Madrid, Spain, ³Rheumatology Department. Hospital universitario 12 de octubre, Instituto de investigacion hospital 12 de octubre (i+12), Madrid, Spain, ⁴Facultad de CC. EE y Empresariales, Universidad de Leon, Leon, Spain, ⁵Rheumatology Department. Hospital universitario 12 de octubre, Instituto de investigacion hospital 12 de octubre (i+12), Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Polymyalgia rheumatic (PMR) is a common rheumatic inflammatory disease in the elderly. Glucocorticoids (GC) are the therapeutic mainstay in PMR but induce significant toxicity…
Abstract Number: 760 • 2019 ACR/ARP Annual Meeting
Prescribing Methotrexate in Polymyalgia Rheumatica: A Missed Opportunity?
Diane Marsman¹, Aatke van der Maas ¹, Nathan den Broeder ¹, Thomas Bolhuis ¹, Nadine Boers ², Alfons den Broeder ¹ and Frank van den Hoogen ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen
Background/Purpose: Patients with polymyalgia rheumatica (PMR) and giant cell arthritis (GCA) constitute approximately 20% of diseases chronically treated with glucocorticoids (GC) with a daily dose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].